Headlines: 'Disgraceful' hosepipe bans and blocked police car
Our pick of local website stories
A mum-of-two who said her breasts "tried to kill [her]" after she was diagnosed with breast cancer just four weeks post-partum is calling for more research into treatment options, Bristol Live reported.After a man died in a Wiltshire river, an ambulance worker who attended the scene is calling for a ban on unsupervised wild swimming, according to Wiltshire 999.The Swindon Advertiser said a trade union in Swindon has called Thames Water's hosepipe ban "disgraceful" and criticised the company for wasting "billions" of litres of water.
Our top three from yesterday
What to watch on social media
A police car on an emergency call was filmed being blocked by planters installed in the East Bristol Liveable Neighbourhood.Salisbury City Hall has defended its decision to host controversial political commentator Katie Hopkins.The "biggest walking Rugby Festival in the world" took place over the weekend.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
12 hours ago
- The Independent
New breast cancer test predicts if disease could return
A new test has been developed to predict whether breast cancer is likely to return just two weeks after treatment begins. Experts suggest this innovation could spare thousands of breast cancer patients from receiving unnecessary treatment. The test targets oestrogen receptor-positive, human epidermal growth factor receptor 2 positive breast cancer, a type accounting for around 200,000 global cases annually. Developed by scientists at The Institute for Cancer Research, London, the test identifies the 6 per cent of patients at highest risk of relapse. The findings aim to facilitate more precise and personalised treatment plans, guiding doctors on which patients need more intensive therapy.
BBC News
20 hours ago
- BBC News
Bridlington man survives breast cancer after daughter's plea
A grandfather who was diagnosed with breast cancer after his daughter encouraged him to see a doctor says he may not have otherwise Firth, 79, from Bridlington, went on to have a double mastectomy after Rachel Firth, 48, recognised his symptoms. Ms Firth said there needed to be more public awareness of breast cancer in men and greater awareness among medical said checking for breast cancer was seen as "very female" and she feels men are "getting forgotten". In June 2017, Mr Firth said he noticed an itch under his arm while changing. His daughter, a pharmacy technician, noticed one of his nipples was inverted, something he had noticed but not paid much attention to. She also noticed a small lump to the seeing the doctor, the grandfather-of-three was diagnosed, had surgery and returned to work within two weeks. His left breast was removed along with his lymph nodes and he had six months of treatment including chemotherapy and the end of his treatment he said he was "glad" to ring a bell on the hospital wall to signal he had completed his treatment before getting the "all clear" about six months Firth said he never thought, as a man, breast cancer would affect said when people found out they were in disbelief. 'Everything's pink' Ms Firth said, when her father went for a breast cancer check-up, a nurse thought he was in the wrong place and another assumed she was having a said: "Everything's pink. Every picture, every pamphlet, everything that is towards breast cancer has got a woman on the front."Mr Firth was diagnosed with breast cancer again in February last year and had surgery to remove his right breast. He said he is now doing well. He is taking part in a parachute jump and a fashion catwalk later this month to raise money for multiple charities. Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here. Download the BBC News app from the App Store for iPhone and iPad or Google Play for Android devices
The Independent
a day ago
- The Independent
Breast cancer breakthrough as new test could revolutionise treatment
A new test for breast cancer patients has been developed which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast cancer patients could be spared unnecessary treatment as a result. The new test has been devised by scientists to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive – which accounts for around 200,000 cases of cancer each year around the globe. Writing in the journal eBioMedicine, experts said the test means that some patients will be able to 'de-escalate' their treatment while it could also help identify those who need 'more intensive therapeutic strategies'. The test, which was developed by scientists at The Institute for Cancer Research, London, correctly identifies the 6% of patients at highest risk of relapse. Researchers analysed tumour samples from 213 patients. They found that two weeks of hormone therapy changes the characteristics of some tumours, causing them to shift their subtype. The patients with the highest risk of cancer returning had a type of tumour called Luminal B that did not change after this short-term hormone therapy. Experts said these patients will require more intensive treatment. They said the findings highlight the benefit of two weeks of hormone therapy before surgery to help guide doctors' decision making. Corresponding author of the study, Dr Maggie Cheang, from The Institute of Cancer Research, London, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'
